Sean Parker
Founder and Chairman @ Parker Institute for Cancer Immunotherapy
San Francisco, United States
Sean Parker is a seed investor at Parker Institute for Cancer Immunotherapy in San Francisco focused on Software and Biotechnology. Sean Parker is the Founder and Chairman of Parker Institute for Cancer Immunotherapy. He previously worked at Spotify as a Board Member and Investor. Sean Parker attended Oakton High School.
- Total investments:
- 25
- Last investment:
- Lead investor:
- 12%
Last updated:
For AI agents: llms.txt
Industries Sean Parker invests in
Stages Sean Parker invests in
Countries Sean Parker invests in
Round sizes
Round size
- Seed
- $1.2M–$12M
- Series A
- $5M–$70M
- Series B
- $23M–$40M
Investment Focus
Industry
- Software 7 (28%)
- Biotechnology 4 (16%)
- Music 3 (12%)
- Internet 3 (12%)
- Messaging 3 (12%)
Stage
- Seed 7 (28%)
- Series A 6 (24%)
- Series B 3 (12%)
- Funding Round 2 (8%)
- Grant 1 (4%)
Country
- United States 16 (64%)
- United Kingdom 2 (8%)
- Australia 1 (4%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Periscan
|
Periscan validates exposure, controls, attack paths, AI applications, and fixes — then turns the results into proof. | $2M / Pre-Seed / Jun 04, 2026 | |
Stability AI
|
Stability AI is an artificial intelligence-driven visual art startup that designs and implements open AI tools. The company focuses on creating open models for various media types, including image, video, 3D, and audio, with applications also targeting enterprise-level needs. Stability AI fosters a vibrant community involving experts and partnersworldwide, enhancing collaboration in developing AI tools. | $80M / Venture - Series Unknown / Jun 25, 2024 | |
IgGenix
|
IgGenix is a biotechnology company, directly address food and other severe allergies by re-engineering key antibodies involved in the allergic cascade. IgGenix isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and possibly prevent the allergic cascade. | $40M / Series B / Feb 06, 2023 | |
ByHeart
|
ByHeart operates as a fully integrated infant nutrition company. It is dedicated to translating leading nutrition science and breastmilk research into evolved foods and formulas to support babies’ health and parents’ peace of mind. Its products strive to be next to nature made from hand-picked ingredients using small-batch blending and sit at theforefront of immune, microbiome, cognitive, and digestive health.The company was founded in 2016 and is headquartered in New York. | $70M / Series A / Apr 15, 2020 | |
RevUp Software
|
RevUp Software is bringing leading-edge, easy to use analytics to Non-Profits, Academic Institutions and Political Organizations. We help fundraisers, while working with existing software, create new ways to identify, target, and engage their networks. | $7.5M / Series A / Oct 01, 2018 | |
Thrive Global
|
Thrive Global is a leading behavior change technology company helping individuals, corporations and communities improve their well-being and performance through our behavior change platform, storytelling and corporate services. Thrive was founded by Arianna Huffington and launched in 2016 with the mission of changing the way we work and live byending the collective delusion that burnout is the price we must pay for success. We offer companies and individuals sustainable, science-based solutions to enhance both mental and physical well-being and performance, purpose and our relationship with technology. We are committed to accelerating this culture shift around the world. Thrive Global is headquartered in New York City and has offices in San Francisco, Athens, Bucharest, Dublin, and Melbourne. For more information, visit www.thriveglobal.com. | $31.7M / Series B / Nov 29, 2017 | |
3T Biosciences
|
Founded in 2017, 3T Biosciences is an immunotherapy company headquartered in Menlo Park, California. | $12M / Seed / Oct 04, 2017 | |
OpenFan
|
OpenFan is arming every business -- small, medium and large -- with Amazon-level customer intelligence. Our analytics platform and data feed surface powerful and actionable consumer insights based on SKU-level purchasing history at more than 1,000 retailers. | Convertible Note / Jul 21, 2017 | |
nura
|
The nuraphone is a new headphone that integrates unique technology to automatically measure your hearing (from the outer ear all the way to the brain) and adapt music perfectly to you. In order for headphones to deliver the right sound, they must be matched to the listener. Nuraphones even recognize you when you put them on. | $4.3M / Seed / May 13, 2017 | |
Emoticast
|
Emoticast is a platform to share music GIFs with sound across all platforms such as iMessage, Facebook Messenger, WhatsApp, etc. | $5M / Seed / Mar 29, 2017 | |
| See all 25 investments → | |||
Co-Investors
About Parker Institute for Cancer Immunotherapy
The Parker Institute for Cancer Immunotherapy brings together the best scientists, clinicians, and industry partners. The company strives to build a smarter and more coordinated cancer immunotherapy research effort to save lives.
Parker Institute for Cancer Immunotherapy Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jeffrey Bluestone
President & CEO
|
|||
|
Sean Parker
Founder and Chairman
|
|||
Charles Michael Yim
Donor
|
|||
Crystal Mackall
Director, Parker Institute for Cancer Immunotherapy at Stanford
|
|||
Crystal Mackall
Director, Parker Institute for Cancer Immunotherapy at Stanford
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Sean Parker invest in?
Sean Parker invests primarily in Software, Biotechnology and Music startups, most often at Seed and Series A stage. Most of the 25 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Sean Parker's check size?
Sean Parker typically joins rounds of $1.2M–$12M at Seed, $5M–$70M at Series A and $23M–$40M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Sean Parker participates in.
When did Sean Parker last invest?
The most recent investment recorded for Sean Parker closed in Jun 2026. Shizune tracks 25 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
